Complete coverage on


Susan Hendricks reports on the health consequences of sleeping with a pet.

Latest Stories

Better alignment could cut need for hip replacementsupdated: Fri Oct 28 2011 12:45:00

On October 4, Brian Williams continued his "NBC Nightly News" report on the "Largest Medical Device Failure Ever," involving "metal-on-metal" hip replacements manufactured by DePuy, a subsidiary of Johnson and Johnson.

Do I have gout or tendinitis?updated: Wed Jun 22 2011 09:52:00

I am 35, female and have elevated levels of uric acid. My doctor wants me tested for gout in my left ankle, but the pain in my ankle didn't start until I began using it to overcompensate for my other injured leg by limping. Will the black cherry concentrate I've heard about in pill form lower the uric acid levels, and how can I tell the difference between gout and tendinitis?

Drugs for psoriasis, arthritis may lower diabetes riskupdated: Tue Jun 21 2011 17:42:00

Drugs that treat psoriasis and rheumatoid arthritis, or RA, by suppressing the immune system may also reduce the risk of developing diabetes, at least in people who already have one of these conditions, according to a new study in the Journal of the American Medical Association.

Fortune: Novartis: We're paying for reform without seeing benefits yetupdated: Tue May 03 2011 14:40:00

Swiss drug maker Novartis AG is facing tough competition from generics as several of its key drugs -- namely, bestseller Diovan for hypertension -- begin to lose patent protection in 2012.

Soda, OJ may increase risk of goutupdated: Wed Nov 10 2010 11:27:00

Drinking too much soda, orange juice, or other sugary drinks appears to increase the risk of developing gout, an especially painful form of arthritis, according to a new study in the Journal of the American Medical Association.

Study: Alcohol may fight rheumatoid arthritisupdated: Tue Jul 27 2010 19:30:00

Moderate drinking has been linked to a variety of health benefits, including a reduced risk of heart disease, stroke, and diabetes. According to a new study, drinking alcohol may also ease the pain of -- and lower the risk of developing -- rheumatoid arthritis, a potentially crippling autoimmune disorder.

Blood test may predict rheumatoid arthritisupdated: Fri Jan 29 2010 14:38:00

A simple blood test may allow doctors to identify a debilitating form of arthritis years before any symptoms appear, which may help to stop the disease in its tracks, new research suggests.

Arthritis mythsupdated: Mon Mar 30 2009 12:39:00

Sorting out fact from fiction is important for arthritis sufferers, as CNN's Judy Fortin reports.

It's not just an old people thing: Arthritis myths debunkedupdated: Mon Mar 30 2009 12:39:00

The bad economy and downturn in the housing market aren't the only painful things for Realtor Anne Stephens. Her knees, hips and ankles hurt from arthritis.

How can someone with arthritis work out?updated: Fri Mar 27 2009 10:13:00

My wife thinks she is fat. I disagree. I would consider her chubby at most. She has self-esteem issues and confidence issues because of her weight. I would like to help her lose weight to make herself feel better, but the only problem is she has arthritis in her wrists and ankles. So is there any type of workout that will help my wife lose weight but not mess with her arthritis in the process? Thank you.

Does surgery help arthritic knees?updated: Mon Dec 22 2008 12:42:00

Nearly one in five people in the U.S. has some form of osteoarthritis. The condition, which can affect joints, can cause severe pain and limit mobility. Arthroscopic surgery is a common form of treatment for OA of the knee, but studies on its effectiveness have shown varying results. A new study finds that arthroscopic surgery may not be the answer for many patients with OA of the knee. Study Doubts Knee Surgery Benefits updated: Thu Sep 11 2008 11:00:00

Nearly a million knee surgeries are performed in North America each year to ease the pain of osteoarthritis -- but researchers say the procedure is a sham Half of US Diabetics Have Arthritisupdated: Thu May 08 2008 19:00:00

The survey of nearly 800,000 people is the first extensive look at the overlap between the two conditions, said Dr. John Klippel, president of the Arthritis Foundation The Ethics of Erasing a Bad Memory updated: Mon Oct 15 2007 12:00:00

Doctor's View: A frightened cancer patient inadvertently heard terrible news. Anesthesia erased her memory. It was a snap decision -- and a compassionate one. But was it right?

CNNMoney: Schering-Plough profits riseupdated: Sun Jul 22 2007 21:50:00

Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies. Hot Dog Eating Champ Diagnosed with Arthritic Jawupdated: Wed Jun 27 2007 22:32:00

Takeru Kobayashi of Japan, the hot-dog eating champ of New York City's Coney Island, may be out of commission for next week's annual July 4th contest.

CNNMoney: Amgen earnings meet forecastsupdated: Mon Apr 23 2007 16:11:00

The biotech Amgen reported first-quarter earnings Monday that matched expectations, though its revenue fell just short of forecasts.

CNNMoney: Judgment day for new Merck painkillerupdated: Tue Apr 10 2007 13:35:00

The moment of truth has come for Arcoxia, Merck's arthritis painkiller intended to replace the withdrawn drug Vioxx.

CNNMoney: Abbott pitches Humira for psoriasisupdated: Mon Apr 02 2007 08:36:00

Abbott Laboratories is trying to get its top-selling blockbuster drug approved for yet another use, which could lead to further sales.

Keep your joints healthy: A complete guide to staying strong updated: Tue Feb 27 2007 10:48:00

About 21 million adults have osteoarthritis -- the wear-and-tear condition that causes achy joints and may eventually lead to can't-get-up-from-the-sofa pain.

CNNMoney: Big Pharma's drug wish list for 2007updated: Thu Dec 21 2006 09:48:00

After a rough couple of years dealing with patent expirations and the often frustrating hunt for new products, drug industry executives would love nothing better than an oracle to predict what products in their labs will become the big blockbuster drugs over the next few years.

CNNMoney: Merck wins another Vioxx caseupdated: Fri Dec 15 2006 13:16:00

Merck & Co. won its second courtroom Vioxx victory this week in a product liability trial, Merck said.

CNNMoney: FDA panel: Approve Celebrex for kids despite riskupdated: Wed Nov 29 2006 15:00:00

Food and Drug Administration advisers voted in favor of approving the Pfizer painkiller Celebrex as an effective treatment of rheumatoid arthritis for children, even though it is not safe.

CNNMoney: Merck: New pain drug safer than Vioxxupdated: Mon Nov 13 2006 08:39:00

Merck & Co. said Monday that its arthritis painkiller Arcoxia does not increase the risk of heart attacks, in a study underscoring the difference between this drug and its withdrawn-from-the-market blockbuster Vioxx.

CNNMoney: Merck sets sights on new arthritis blockbusterupdated: Fri Nov 10 2006 09:21:00

Merck is experimenting with a new arthritis painkiller that could replace Vioxx, the former billion-dollar blockbuster that has proven to be a liability for the company.

CNNMoney: Novartis pain drug battles Vioxx stigmaupdated: Tue Nov 07 2006 12:37:00

Novartis plans to bring a new arthritis painkiller to the U.S. market, but analysts say its similarity to the disgraced drug Vioxx could kill its chances of becoming a billion-dollar blockbuster.

CNNMoney: Life after Vioxx is good for Celebrexupdated: Tue Sep 19 2006 13:18:00

In the nearly two years since Merck pulled its tainted blockbuster Vioxx from the market, Pfizer has enjoyed a monopoly-like market for its own arthritis drug, Celebrex.

CNNMoney: Abbott's Humira: More uses, more moneyupdated: Thu Aug 31 2006 13:26:00

Abbott Labs' fast-growing flagship drug Humira is grabbing market share and making money ... and now the company is trying to win the blessings of the FDA to make more.

CNNMoney: Eli Lilly hit with $65M damagesupdated: Fri May 05 2006 08:16:00

A federal jury ruled that Eli Lilly & Co. infringed the patent of Ariad Pharmaceuticals with its drugs Evista and Xigris, and ordered the drugmaker to pay the Massachusetts biotech firm $65.2 million, the companies said.

CNNMoney: Merck stock tumbles after Vioxx verdictupdated: Thu Apr 06 2006 09:31:00

Merck stock tumbled Thursday, a day after the nation's No. 2 drugmaker was found liable for the heart attack of a New Jersey man who took Vioxx and a jury awarded $4.5 million in damages.

CNNMoney: Could Celebrex prevent colorectal cancer?updated: Mon Apr 03 2006 09:46:00

Celebrex, an arthritis painkiller from Pfizer, could be used to prevent colorectal cancer, according to studies revealed today by the American Association for Cancer Research.

This week in the medical journalsupdated: Fri Mar 03 2006 07:18:00

Benefits may outweigh risks

CNNMoney: FDA takes a closer look at withdrawn MS drugupdated: Thu Feb 23 2006 13:08:00

The FDA's balancing act between safety and speed is taking center stage with the multiple sclerosis drug Tysabri.

CNNMoney: More good times ahead for biotechsupdated: Thu Feb 23 2006 09:21:00

Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.

CNNMoney: Good times ahead for biotechsupdated: Wed Feb 22 2006 14:55:00

Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.

CNNMoney: Mistrial declared in Merck caseupdated: Mon Dec 12 2005 09:55:00

A federal judge declared a mistrial Monday in the latest lawsuit against Merck concerning its painkiller Vioxx, attorneys for both the plaintiff and drugmaker said.

This week in the medical journalsupdated: Thu Sep 15 2005 14:06:00

The "art" of medicine -- a term that doctors often fall back on when the "science" of medicine is open to interpretation -- was illustrated by studies in the leading medical journals this week.

CNNMoney: Arthritis drug moves towards approvalupdated: Tue Sep 06 2005 15:04:00

An FDA advisory panel voted unanimously in favor of abatacept, a Bristol-Myers Squibb treatment for rheumatoid arthritis, a move that often precedes FDA approval.

CNNMoney: Bristol facing two key FDA panel votesupdated: Tue Aug 23 2005 13:36:00

Bristol-Myers Squibb faces votes by FDA advisory panels on two key drugs in its pipeline, decisions that could affect the company's financial future for years to come.

CNNMoney: Plaintiff testifies in first Vioxx trialupdated: Thu Aug 04 2005 08:25:00

The plaintiff in the first of several thousand Vioxx lawsuits took the stand in a Texas court Thursday and said she is taking antidepressants to alleviate the sorrow from her husband's death.

CNNMoney: Judge denies Merck request in Vioxx caseupdated: Tue Jul 05 2005 09:55:00

A Texas judge rejected Merck's request to postpone its July 11 court date for the first in a series of lawsuits involving Vioxx, an arthritis painkiller the company withdrew last year because of health risks, according to a court spokesperson.

CNNMoney: Texas AG sues Merck over Vioxxupdated: Thu Jun 30 2005 15:10:00

The Texas Attorney General sued Merck Thursday, accusing the drug company of misrepresenting the safety of arthritis painkiller Vioxx, the attorney general's office said.

CNNMoney: Celebrex prescriptions plunge 40 percentupdated: Wed Jun 29 2005 11:57:00

The health risks surrounding arthritis painkillers have caused physicians to back away from prescribing Celebrex, rather than propping up sales for the sole remaining cox-2 inhibitor on the market, according to an analyst report.

CNNMoney: Could Celebrex survive a black box?updated: Tue May 03 2005 10:48:00

The black box label is the most potent warning in the Food and Drug Administration's arsenal, but it is not necessarily a death knell for drug sales, analysts say.

FSB: Betting on a Cureupdated: Sun May 01 2005 00:01:00

Maybe you're Diabetic, or someone close to you is. Or maybe Alzheimer's disease runs in your family. If so, Sam Katz, CEO of WellSpring BioCapital Partners, considers you his target market--a "pass...

CNNMoney: Canada OKs cannabis oral sprayupdated: Fri Apr 29 2005 12:41:00

A cannabis-based painkiller for sufferers of multiple sclerosis is expected to be in Canadian pharmacies this summer, but whether it appears on U.S. pharmacy shelves is a key question.

CNNMoney: FDA statement on Celebrex, Bextraupdated: Thu Apr 07 2005 10:49:00

The Food and Drug Administration asked Pfizer and other manufacturers to revise their labels to include boxed warnings of potential cardiovascular risks and gastrointestinal bleeding from certain arthritis drugs. The FDA also asked Pfizer to withdraw Bextra from the market. Following is the FDA's statement:

Fortune: Pfizer statement on Celebrex, Bextraupdated: Thu Apr 07 2005 10:40:00

Pfizer Inc. agreed Thursday to change the warning labels on its arthritis drug Celebrex and pull Bextra off the market after regulators expressed concerns about the arthritis medicines' safety. Following is Pfizer's statement:

CNNMoney: FDA statement on Pfizer recallupdated: Thu Apr 07 2005 10:30:00

Pfizer Inc. said Thursday that the Food and Drug Administration asked it to pull its arthritis painkiller Bextra from the market. The following is from the FDA statement:

CNNMoney: Pfizer pulls Bextra off the marketupdated: Thu Apr 07 2005 09:19:00

Pfizer Inc. said Thursday it is pulling its arthritis painkiller Bextra off the market after the Food and Drug Administration asked for the recall.

CNNMoney: Rheumatoid arthritis drugs get tractionupdated: Wed Apr 06 2005 09:11:00

Two drug candidates that would reduce the symptoms of rheumatoid arthritis have passed testing, announced drug manufacturers Human Genome Sciences, Roche, Genentech and Biogen Idec on Wednesday, offering hope where arthritis treatments have raised health concerns.

CNNMoney: Kickoff to gains?updated: Mon Feb 07 2005 05:30:00

A pullback in oil prices Monday combined with strength in the dollar could put stocks in rally mode at the start of a new trading week on Wall Street.

FDA urges limits on Celebrex, Bextraupdated: Thu Dec 23 2004 15:10:00

The Food and Drug Administration issued a public health advisory Thursday, recommending doctors limit the use of Pfizer Inc.'s Celebrex and Bextra to patients who can't take other pain medicines.

FDA warns naproxen usersupdated: Tue Dec 21 2004 02:41:00

The Food and Drug Administration issued a warning to users of the over-the-counter pain reliever naproxen Monday after federal researchers found an increased number of heart attacks and strokes among users.

CNNMoney: Pfizer pulling ads for Celebrexupdated: Mon Dec 20 2004 07:29:00

Under pressure from regulators, Pfizer has agreed to limit advertising of Celebrex after a clinical trial showed the painkiller was linked to an increased risk of heart attacks and strokes.

CNNMoney: Pfizer's statement on Celebrexupdated: Fri Dec 17 2004 12:20:00

Pfizer Inc., the world's largest drugmaker, said Friday that a study found an increased risk of heart attacks to patients using its popular arthritis drug Celebrex, but the company said it has no plans to pull the painkiller from the market.

FDA: Consider 'alternative' to Celebrexupdated: Fri Dec 17 2004 10:54:00

With a new study that indicates the nation's leading arthritis painkiller could raise the risk of heart attacks, the Food and Drug Administration advised doctors Friday to consider "alternative therapy" to Celebrex.

CNNMoney: Pfizer cites Celebrex heart attack riskupdated: Fri Dec 17 2004 09:36:00

Pfizer Inc. said Friday it had no plans to pull the popular painkiller Celebrex off the market despite data showing that patients using the drug in a long-term cancer study had more than double the risk of a heart attack.

CNNMoney: NY state pension fund sues Merckupdated: Tue Nov 30 2004 16:07:00

The New York State pension fund sued Merck & Co. Tuesday, claiming to have suffered huge financial losses from the scandal surrounding the drugmaker's Vioxx painkiller.

CNNMoney: Drug stocks feel the heatupdated: Fri Nov 19 2004 11:15:00

Drug stocks took another hit Friday, a day after a veteran Food and Drug Administration researcher said that five drugs currently on the market needed closer scrutiny for possible safety risks.

CNNMoney: Merck: Vioxx pulled when risk was seenupdated: Tue Nov 16 2004 11:50:00

The chairman of pharmaceutical heavyweight Merck said Tuesday its arthritis drug Vioxx was pulled from the market at the earliest indication of problems.

Fortune: Will Merck Survive Vioxx?updated: Mon Nov 01 2004 00:01:00

Listening to Ray Gilmartin, you can't help but be struck by how matter-of-fact and calm the man seems. The 63-year-old Merck chairman and CEO is soft-spoken, quick with a smile, and unfailingly pol...

CNNMoney: Pfizer warns of Bextra heart riskupdated: Fri Oct 15 2004 08:14:00

Drug manufacturer Pfizer said Friday that its Bextra drug, seen as an alternative to Merck's Vioxx arthritis medication, may raise heart attack risk in high-risk bypass surgery patients.

Firm warns doctors of arthritis drug riskupdated: Fri Oct 08 2004 10:53:00

Johnson & Johnson says its rheumatoid arthritis drug Remicade may put patients at higher risk for lymphoma, and the company is sending out warning letters to physicians.

CNNMoney: Mixed day, tough quarterupdated: Thu Sep 30 2004 09:46:00

The Dow tumbled and the broader market was mixed Thursday, as investors struggled to make end-of-quarter moves and dealt with a big setback after Merck withdrew one of its key drugs from the market.

CNNMoney: Dow gets Merck'dupdated: Thu Sep 30 2004 09:16:00

Merck's withdrawal of its arthritis treatment sent the stock tumbling more than 25 percent and pushed the Dow into deeply negative territory at the open Thursday.

CNNMoney: Merck yanks arthritis drug Vioxxupdated: Thu Sep 30 2004 07:26:00

Merck & Co. on Thursday recalled its arthritis drug Vioxx after an ongoing trial confirmed the medication increases the risk of heart attack and strokes. The news sent stock down nearly 27 percent and erased $25 billion from its market value.

Fortune: Elite Factoriesupdated: Mon Sep 06 2004 00:01:00

A common thread connects this year's standouts: They all responded to crisis by radically changing the way they make things. Autoliv reprocessed its factory to fend off stiff competition in airbags...

Fortune: Growing Against The Grain Amgen CEO Kevin Sharer stands accused of remaking the world's biggest biotech company in the image of updated: Mon May 03 2004 00:01:00

The Empire State ballroom at the Grand Hyatt Hotel in midtown Manhattan typically serves as the setting for the kind of stuffy, state-of-a-business luncheons that are more snooze inducing than buzz...

Tai Chi may aid in arthritis treatmentupdated: Fri Mar 12 2004 09:45:00

When it comes to working out, no exercise regimen is "one size fits all," but one particular martial art form comes pretty close.


For years we've heard that the pharmaceutical sector is the closest we have come to a sure thing in the world of investing. We practically know the arguments by heart. America is aging: We need mor...

Money Magazine: 10 drug stocks to watchupdated: Mon Mar 24 2003 15:43:00

In the future, successful drug companies will have to come up with innovative cures for complex, hard-to-treat conditions like cancer -- without letting their research-and-development spending get out of hand.

Fortune: Biotech's New Colossus Move over, Big Pharma. Amgen boasts better growth.updated: Mon Apr 15 2002 00:01:00

For years Amgen has seemed biotechnology's best answer to the likes of Merck--a sector leader with so much heft and momentum that you'd recommend its stock to your mom. But now making that analogy ...

Fortune: Finding The Bulls In Biotech The sector is blazing, the science ever more titillating. But with share prices up 214% in three yeupdated: Mon Feb 04 2002 00:01:00

On Dec. 17, Amgen, the flagship company of the biotechnology world, closed the biggest merger in the sector's history. It agreed to pay $16 billion to buy rival Immunex, primarily for the right to ...

Fortune: There's Still Gold In Them Thar Pills The era of the blockbuster drug is ending--but genomics will take pharma to new highs.updated: Mon Jul 23 2001 00:01:00

In a queasy, headachy economy like this one, it's easy to understand why investors would reach for the medicine chest. Pharmaceuticals stocks have shone for decades as growth stalwarts relatively u...

Money Magazine: Health Consumer The news on Lyme disease, sunscreen, weight control and moreupdated: Tue Aug 01 2000 00:01:00

HELP KIDS FIGHT FAT Obesity isn't just a health threat to the middle-aged anymore; today 11% of American kids are overweight, up from 5% 20 years ago. A new weapon in the fight against fat: the fir...

Fortune: Biotech Bonanza Biotech has been one of the market's hottest sectors in recent months. Are there still healthy bargains to be haupdated: Mon Nov 08 1999 00:01:00

Like all mass hysterias, dementia induces serious tunnel vision. Witness investors' delayed reaction to the biotech industry's recent winning streak at the FDA. For more than a year the bio...

Money Magazine: Small-Caps to Watchupdated: Sun Aug 01 1999 00:01:00

XIRCOM The connection for remote PC users

Money Magazine: Pain, Pain Go Away Is Celebrex--the new arthritis drug--all it's cracked up to be?updated: Thu Apr 01 1999 00:01:00

As many of America's 23 million arthritis sufferers know all too well, the pills that provide welcome relief from joint pain and inflammation may, over time, also cause stomach trouble, ranging fro...

Fortune: The Checkup, Part II A year ago the author tested the Mayo Clinic's Executive Health Program. His return visit proves the benefiupdated: Mon Oct 26 1998 00:01:00

Everyone who saw me that night--nurses, residents, doctors, technicians, and emergency room attendants--said the same thing: What I was experiencing was the male equivalent of labor pain. I agreed....

Fortune: Why Pfizer Is So Hot With one of the richest product pipelines in the FORTUNE 500, Pfizer is on a roll that will continue for yeupdated: Mon May 11 1998 00:01:00

One day last March, after rivals Glaxo Wellcome, American Home Products, and others announced they were exploring multibillion-dollar mergers, Pfizer CEO William Steere went to the fitness center i...

Fortune: CELL SUICIDE THE BIRTH OF A MEGA-MARKETupdated: Mon May 15 1995 00:01:00

For 11 lonely years cell biologist L. David Tomei toiled away in the Columbus labs of Ohio State University, exploring a process known as apoptosis--programmed cell death, in which the body divides...

Fortune: Uncle Sam Wants Nonprofit Profitsupdated: Mon Nov 14 1994 00:01:00

The Internal Revenue Service and charities are slugging it out again. Nonprofit groups keep launching new money-raising ventures, like this fall's splashy fashion industry T-shirt sale that will be...

Fortune: WHY DRUG PRICES WILL GO LOWER The industry's days of gargantuan earnings are gone forever. Why? Managed-care outfits are demandiupdated: Mon May 03 1993 00:01:00

PHARMACEUTICAL companies have long had the best deal in American business, a foolproof formula for turning chemical compounds into gold. The industry followed its own set of rules, raising prices a...

Fortune: TREATING PLAIN OLD PAIN updated: Mon Mar 22 1993 00:01:00

A bewildering choice confronts anyone with a garden variety pain like a headache, a stomachache, or a sprained ankle. Are you better off taking aspirin, Motrin IB, Advil, Nuprin, Tylenol, or one of...

Fortune: MEDCO CONTAINMENT SYSTEMS Rx FOR COSTS: DRUGS BY MAILupdated: Mon Aug 24 1992 00:01:00

EVERY ONCE in a while somebody gets a bright idea that winds up revolutionizing an industry. Martin Wygod did, and now his company, Medco Containment Systems, is turning the $60-billion-a-year phar...

Fortune: Listening in on Stalin, what's bigger than the gender gap, seven powerful professors, and other matters. MODEM MAGICupdated: Mon Jul 27 1992 00:01:00

That these are wonderful times for aging neoconservative hypochondriacs with modems was borne out yet again on a recent Sunday morning around 6 A.M. This was when your servant awoke with a swollen,...

Fortune: BIOTECH FIRMS TACKLE THE GIANTS Traditional pharmaceutical companies once derided these startups as ''gene jockeys,'' but bold eupdated: Mon Aug 12 1991 00:01:00

MENTION drug companies and you'll most likely think of such household names as Merck, Lilly, Johnson & Johnson, or Bristol-Myers Squibb. But some fresh new players are on the brink of glory. After ...

Fortune: DRUGMAKERS UNDER ATTACK . Marketing muscle, patent protection, and a unique relationship with their customers have made them Ameupdated: Mon Jul 29 1991 00:01:00

NO AMERICAN INDUSTRY has ever defied the laws of economic gravity like pharmaceuticals. For the past 30 years the drugmakers of the FORTUNE 500 have enjoyed the fattest profits in big business. The...

Fortune: THE NEW ATTACK ON KILLER DISEASES There's fresh hope for ailments from cancer to Alzheimer's. Understanding the genetic and moleupdated: Mon Apr 22 1991 00:01:00

BUGS -- viruses and bacteria -- cause most minor diseases, and some of the major ones like AIDS. But many of the real killers and cripplers, including cancer, heart disease, rheumatoid arthritis, a...

Fortune: COVER STORY SCIENCE SCORES A CANCER BREAKTHROUGH Scientists have identified substances from the body's immune system that could updated: Mon Nov 25 1985 00:01:00

CAUTIOUS CLINICAL investigators fear the familiar phrase ''cancer breakthrough'' almost as much as laymen dread the word cancer itself. Surgery, chemicals, and radiation have so far failed to win t...

We recommend